« Back to Medicines list

Exelon Transdermal Patches

  • Name:

    Exelon Transdermal Patches

  • Company:
    info
  • Active Ingredients:

    Rivastigmine

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 12/10/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 20/11/2019

Click on this link to Download PDF directly

Novartis Ireland Limited

Novartis Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Aclasta 5 mg solution for infusion Active Ingredients Zoledronic acid monohydrate
Medicine Name Afinitor Tablets Active Ingredients Everolimus
Medicine Name Aimovig Active Ingredients Erenumab
Medicine Name Atectura Breezhaler Active Ingredients Glycopyrronium bromide, Indacaterol acetate
Medicine Name Atriance 5 mg/ml solution for infusion Active Ingredients Nelarabine
Medicine Name Azarga 10mg/ml + 5mg/ml eye drops, suspension Active Ingredients Brinzolamide, Timolol Maleate
Medicine Name Azopt 10mg/ml eye drops suspension Active Ingredients Brinzolamide
Medicine Name Cataflam 50 mg Coated Tablets Active Ingredients Diclofenac Potassium
Medicine Name Certican Tablets Active Ingredients Everolimus
Medicine Name CILOXAN 3 mg/ml ear drops, solution Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Co-Diovan 160 mg/12.5 mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 160mg/25mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 320mg/12.5mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 320mg/25mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 80mg/12.5mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Cosentyx 150 mg solution for injection in pre-filled pen Active Ingredients secukinumab
Medicine Name Desferal 500mg Vials Active Ingredients Desferrioxamine Mesylate
Medicine Name Diovan 160 mg film-coated tablets Active Ingredients Valsartan
Medicine Name Diovan 320mg film-coated tablets Active Ingredients Valsartan
Medicine Name Diovan 3mg/ml Oral Solution Active Ingredients Valsartan
Medicine Name Diovan 40 mg film-coated tablets Active Ingredients Valsartan
Medicine Name Diovan 80 mg film-coated tablets Active Ingredients Valsartan
Medicine Name DuoTrav Eye Drops Solution Active Ingredients Timolol Maleate, Travoprost
Medicine Name Enerzair Breezhaler Active Ingredients Glycopyrronium bromide, Mometasone Furoate, indacaterol acetate
Medicine Name Entresto 24mg/26mg, 49mg/51mg and 97mg/103mg film-coated tablets Active Ingredients Sacubitril, Valsartan
1 - 0 of 117 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 12 October 2020 PIL

Reasons for updating

  • Change to name of manufacturer

Updated on 10 December 2019 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 20 November 2019

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 8 - Marketing authorisation number(s)

Updated on 8 April 2019

Reasons for updating

  • File format updated to PDF

Updated on 20 September 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 21 May 2018

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Address change due to BREXIT

Updated on 6 March 2018

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 6 March 2018 SPC

Reasons for updating

  • Improved presentation of SPC
  • Change from individual to joint SPC

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SmPCs changed from individual to joint, some typographical changes have been made

Updated on 19 May 2016 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to MA holder contact details

Updated on 12 January 2016 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 3 September 2015 PIL

Reasons for updating

  • Change to MA holder contact details

Updated on 9 December 2014 PIL

Reasons for updating

  • Change of manufacturer

Updated on 29 November 2013 PIL

Reasons for updating

  • Change of manufacturer

Updated on 30 August 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 31 August 2012 PIL

Reasons for updating

  • Addition of joint PIL covering all presentations

Updated on 14 April 2009 PIL

Reasons for updating

  • Change to drug interactions
  • PIL retired pending re-submission

Updated on 6 November 2008 SPC

Reasons for updating

  • Change to section 9 - Date of renewal of authorisation
  • Joint SPC superseded by SPCs for individual presentations

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

date of renewal has been amended

Updated on 21 October 2008 SPC

Reasons for updating

  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.5 The following statement has been added " Caution is recommended when selecting anaesthetic agents. Possible dosage adjustments or temporarily stopping treatment can be considered if needed"
4.7 Inclusion of the following statement: "As a consequence, rivastigmine has minor or moderate influenses on the ability to drive and use machines".

Updated on 3 September 2008 SPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 Changes made to Sections 4.5, 4.7 and Section 10.

Updated on 14 May 2008 PIL

Reasons for updating

  • New PIL for new product

Updated on 7 January 2008 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)